Aldeyra Therapeutics, Inc. (ALDX) EPS Estimated At $-0.39

July 14, 2018 - By Eula Gilbert

Investors sentiment increased to 3 in Q1 2018. Its up 1.38, from 1.62 in 2017Q4. It improved, as 3 investors sold Aldeyra Therapeutics, Inc. shares while 6 reduced holdings. 10 funds opened positions while 17 raised stakes. 10.28 million shares or 3.03% more from 9.98 million shares in 2017Q4 were reported.
Prelude Cap Mngmt Ltd Liability owns 2,731 shares or 0% of their US portfolio. Missouri-based Stifel Fincl has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Adage Cap Prtnrs Grp Ltd Llc reported 750,000 shares stake. Tower Rech Capital Lc (Trc) has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Perceptive Limited Liability reported 3.09 million shares. Mangrove Prns has 0.16% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 324,019 shares. Moreover, Woodstock Corporation has 0.1% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 67,759 shares. Vanguard Gp Inc stated it has 697,634 shares. Barclays Public Limited Com, United Kingdom-based fund reported 1 shares. 683 Management Ltd Llc reported 0.66% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Hightower Advsrs Ltd Co accumulated 19,250 shares. Manufacturers Life Insur The stated it has 139 shares or 0% of all its holdings. Bank Of America Corp De holds 0% or 4,615 shares. Moreover, Renaissance Techs Ltd Liability has 0% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Blackrock accumulated 0% or 39,407 shares.

Analysts expect Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to report $-0.39 EPS on August, 14.They anticipate $0.04 EPS change or 11.43 % from last quarter’s $-0.35 EPS. After having $-0.43 EPS previously, Aldeyra Therapeutics, Inc.’s analysts see -9.30 % EPS growth. The stock increased 1.79% or $0.15 during the last trading session, reaching $8.55. About 94,454 shares traded. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has risen 82.11% since July 14, 2017 and is uptrending. It has outperformed by 69.54% the S&P500.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Coverage

Among 2 analysts covering Aldeyra Therapeutics (NASDAQ:ALDX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics had 4 analyst reports since January 26, 2018 according to SRatingsIntel. The stock of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) earned “Buy” rating by Cantor Fitzgerald on Thursday, March 29. The stock has “Buy” rating by Cantor Fitzgerald on Tuesday, June 26. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, May 15.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $171.94 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

More recent Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) news were published by: which released: “Aldeyra Therapeutics Joins the Russell 3000® and 2000® Indexes” on June 25, 2018. Also published the news titled: “Aldeyra Therapeutics Announces 2018 Research Day” on June 20, 2018.‘s news article titled: “Aldeyra Therapeutics (ALDX) Reports Last Patient Dosed in Dry Eye Disease Phase 2b Clinical Trial” with publication date: July 12, 2018 was also an interesting one.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.